Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2026 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungenAcceptable Use
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to Reports
Fundraising

Observe

Observe Raises $115M in Series C

San Mateo, CAOctober 13, 20252 min read
Employees
100+

Observe Raises $115M in Series C


Observe has successfully raised $115M in a Series C at a $650M valuation led by Sutter Hill Ventures, Madrona.


Company Overview


Observe is a Observability company headquartered in San Mateo, CA, founded in 2017 with 100+ employees.


Observability platform built on Snowflake for DevOps


Fundraising Details


  • Amount Raised: $115M
  • Round Type: Series C
  • Valuation: $650M
  • Date: 2025-10-13
  • Investors: Sutter Hill Ventures, Madrona

About Observe


Observability platform built on Snowflake for DevOps The company is positioned in the Observability sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: San Mateo, CA
  • Founded: 2017
  • Team Size: 100+
  • Industry: Observability

What This Means


This funding round demonstrates strong investor confidence in Observe's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Observability sector continues to attract significant investment as companies innovate to meet evolving market demands. Observe's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $650M valuation marks an important milestone for Observe, positioning the company among notable players in the Observability industry.


Looking Ahead


With this new capital, Observe is well-positioned to execute on its growth strategy and continue building innovative solutions in the Observability space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-10-13. For more information about Observe, visit their headquarters at San Mateo, CA.

Company Info

Headquarters
San Mateo, CA
Founded
2017
Team Size
100+

Topics

Fundraising(2912)Series C(300)ObservabilityObserve

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free